Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 742-748

  Hensgens, Marjolein P M ^a   Goorhuis, Abraham ^b   Dekkers, Olaf M ^a   Kuijper, Ed J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic use; Case control study; CDI; Risk factor

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CARBAPENEM; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLINDAMYCIN; CYTOSTATIC AGENT; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; METRONIDAZOLE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TRIMETHOPRIM; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIARRHEA; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HOSPITAL PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; RIBOTYPING; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RISK FACTORS; TIME FACTORS;

EID: 84856959278     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr508     Document Type: Article

References (32)

1. Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 2009; 30: 57-66.
2. HPA. Healthcare-Associated Infections and Antimicrobial Resistance:09/10. 2010. http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1281954478156 (date last accessed, 21 December 2010).
3. Dubberke ER, Butler AM, Reske KA et al. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis 2008; 14: 1031-8.
4. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005; 173: 1037-42.
5. Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S4-11.
6. Yip C, Loeb M, Salama S et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001; 22: 572-5.
7. Owens RC Jr, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-31.
8. Dubberke ER, Reske KA, Yan Y et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45: 1543-9.
9. Wistrom J, Norrby SR, Myhre EB et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43-50
10. Bajaj JS, Ananthakrishnan AN, Hafeezullah M et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010; 105: 106-13.
11. Henrich TJ, Krakower D, Bitton A et al. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009; 15: 415-22.
12. Debast SB, Vaessen N, Choudry A et al. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect 2009; 15: 427-34.
13. Weiss B, Kleinkauf N, Eckmanns T et al. Risk factors related to a hospital-associated cluster of Clostridium difficile PCR ribotype 027 infections in Germany during 2007. Infect Control Hosp Epidemiol 2009; 282-4.
14. Dial S, Kezouh A, Dascal A et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008;9: 767-72.
15. Nuila F, Cadle RM, Logan N et al. Antibiotic stewardship and Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2008; 29: 1096-7.
16. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-79.
17. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
18. Paltansing S, van den Berg RJ, Guseinova RA et al. Characteristics and incidence of Clostridium difficile-associated disease in the Netherlands, 2005. Clin Microbiol Infect 2007; 13: 1058-64.
19. Bidet P, Lalande V, Salauze B et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 2000; 38: 2484-7.
20. Knol MJ, Vandenbroucke JP, Scott P et al. What do case-control studies estimate? Survey of methods and assumptions in published case-control research. Am J Epidemiol 2008; 168: 1073-81.
21. de MR, Jager KJ, Zoccali C et al. The effect of joint exposures: examining the presence of interaction. Kidney Int 2009; 75: 677-81.
22. Nord CE, Gajjar DA, Grasela DM. Ecological impact of the des-F(6)-quinolone, BMS-284756, on the normal intestinal microflora. Clin Microbiol Infect 2002; 8: 229-39.
23. Jernberg C, Lofmark S, Edlund C et al. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010; 156: 16-23.
24. Wilson KH. The microecology of Clostridium difficile. Clin Infect Dis 1993; 16 Suppl 4: S214-8.
25. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-60.
26. Carignan A, Allard C, Pepin J et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 2008;46: 1838-43.
27. Hernan MA, Robins JM. Instruments for causal inference: an epidemiologist's dream? Epidemiology 2006; 17: 360-72.
28. Goorhuis A, van Dissel JT, Kuijper EJ. Novel risk factors for Clostridium difficile-associated disease in a setting of endemicity? Clin Infect Dis 2008; 47: 429-30.
29. Eastwood K, Else P, Charlett A et al. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 2009; 47: 3211-7.
30. Crobach MJ, Dekkers OM, Wilcox MH et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009; 15: 1053-66.
31. Garey KW, Graham G, Gerard L et al. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother 2006; 40: 1030-4.
32. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51: 1339-50.